Table 1.
Clinicopathological characteristics in gastric cancer patients with different PCDH8 expressions
| Features | PCDH8 expression in gastric cancer tissue | ||||
|---|---|---|---|---|---|
| Low | High | ||||
| Number of patients | % | Number of patients | % | P‐value | |
| Total | 105 | 72.9 | 39 | 27.1 | |
| Age | |||||
| ≤50 | 21 | 87.5 | 3 | 12.5 | .078 |
| >50 | 84 | 70.0 | 36 | 30.0 | |
| Sex | |||||
| Female | 24 | 72.7 | 9 | 27.3 | .978 |
| Male | 81 | 73.0 | 30 | 27.0 | |
| Differential status | |||||
| Undifferentiated/poorly | 87 | 71.3 | 35 | 28.7 | .307 |
| Moderate/well | 18 | 81.8 | 4 | 18.2 | |
| T | |||||
| T1/2 | 16 | 76.2 | 5 | 23.8 | .715 |
| T3/4 | 89 | 72.4 | 34 | 27.6 | |
| N | |||||
| N0 | 28 | 77.8 | 8 | 22.2 | .449 |
| N1/2/3 | 77 | 71.3 | 31 | 28.7 | |
| Vascular invasion | |||||
| Negative | 44 | 74.6 | 15 | 25.4 | .709 |
| Positive | 61 | 71.8 | 24 | 28.2 | |
| Nerve invasion | |||||
| Negative | 45 | 76.3 | 14 | 23.7 | .450 |
| Positive | 60 | 70.6 | 25 | 29.4 | |
| Stage | |||||
| I/II | 35 | 79.5 | 9 | 20.5 | .235 |
| III/IV | 70 | 70.0 | 30 | 30.0 | |
| 3‐year progression free survival | 60 | 57.1 | 17 | 43.6 | .147 |
| 3‐year overall survival | 67 | 63.8 | 19 | 48.7 | .101 |
PCDH8, protocadherin‐8.